Analyst Price Targets — NBIX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 9:16 pm | — | Wolfe Research | $160.00 | $128.38 | TheFly | Neurocrine initiated with an Outperform at Wolfe Research |
| February 17, 2026 2:53 pm | Danielle Brill | Truist Financial | $140.00 | $128.98 | TheFly | Neurocrine price target lowered to $140 from $169 at Truist |
| February 12, 2026 2:29 pm | — | Needham | $185.00 | $125.38 | TheFly | Neurocrine price target lowered to $185 from $187 at Needham |
| February 12, 2026 2:26 pm | — | RBC Capital | $177.00 | $124.16 | TheFly | Neurocrine price target lowered to $177 from $180 at RBC Capital |
| February 12, 2026 2:08 pm | — | Wedbush | $151.00 | $125.09 | TheFly | Neurocrine price target raised to $151 from $149 at Wedbush |
| February 12, 2026 1:12 pm | — | Morgan Stanley | $173.00 | $126.04 | TheFly | Neurocrine price target lowered to $173 from $175 at Morgan Stanley |
| February 12, 2026 11:06 am | — | H.C. Wainwright | $192.00 | $137.44 | TheFly | Neurocrine price target lowered to $192 from $198 at H.C. Wainwright |
| January 23, 2026 12:41 pm | — | UBS | $178.00 | $137.37 | TheFly | Neurocrine price target lowered to $178 from $188 at UBS |
| January 8, 2026 12:55 pm | — | Truist Financial | $169.00 | $140.62 | TheFly | Neurocrine price target lowered to $169 from $172 at Truist |
| January 8, 2026 11:22 am | — | Morgan Stanley | $175.00 | $140.62 | TheFly | Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley |
Latest News for NBIX
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: TD Cowen 46th Annual Health Care Conference. Fireside chat on Tuesday, March 3, 2026 at 11:50 AM ET in Boston Leerink Global Healthcare Conference.
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation, which the President raised to 15% from 10% over the weekend after the Supreme Court struck it down last Friday, was one of... Here Are Tuesday's Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital,…
COIN, NBIX and UPST have been added to the Zacks Rank #5 (Strong Sell) List on February 18th, 2026.
JPMorgan Chase and Co. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 11.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,730,152 shares of the company's stock after purchasing an additional 468,405 shares during the period. JPMorgan
Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, including muscarinic agonist and glutamate modulator programs, appears significantly underappreciated by the market. Ingrezza's revenue growth is slowing due to pricing pressures, but NBIX's robust cash position and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NBIX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.